ERBB2 and cardiomyopathy: Although the mechanism of trastuzumab-induced cardiomyopathy is not well defined, its relationship to epidermal growth signal pathway HER2 within the heart suggests that cardiotoxicity generated by trastuzumab may be related to the hindrance of HER2 [164].